 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
6 News |  |
- | ETD001 / Enterprise Therap
Preclinical, Journal: ETD001: A novel inhaled ENaC blocker with an extended duration of action in vivo. (Pubmed Central) - Jun 9, 2024
These data support that the ENaC blocker hypothesis is yet to be appropriately tested in pwCF. ETD001 has a profile that enables dosing at a level sufficient to provide a long duration of action in a Phase 2 clinical study in pwCF scheduled for 2024.
- | QBW276 / Novartis
Trial completion, Enrollment change: Safety, Pharmacokinetics and Pharmacodynamics Study of Inhaled QBW276 in Patients With Cystic Fibrosis (clinicaltrials.gov) - Jul 16, 2019
P1/2, N=16, Completed, Sponsor: Novartis Pharmaceuticals
ETD001 has a profile that enables dosing at a level sufficient to provide a long duration of action in a Phase 2 clinical study in pwCF scheduled for 2024. Recruiting --> Completed | N=56 --> 16
- || QBW276 / Novartis
Trial completion date, Trial primary completion date: Safety, Pharmacokinetics and Pharmacodynamics Study of Inhaled QBW276 in Patients With Cystic Fibrosis (clinicaltrials.gov) - Feb 27, 2018
P1/2, N=56, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | N=56 --> 16 Trial primary completion date: Sep 2019 --> Jan 2019 | Trial completion date: Sep 2019 --> Jan 2019
- |||| QBW276 / Novartis
Enrollment open: Safety, Pharmacokinetics and Pharmacodynamics Study of Inhaled QBW276 in Patients With Cystic Fibrosis (clinicaltrials.gov) - Nov 14, 2017
P1/2, N=56, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Sep 2019 --> Jan 2019 | Trial completion date: Sep 2019 --> Jan 2019 Not yet recruiting --> Recruiting
- ||| QBW276 / Novartis
Trial initiation date, Trial primary completion date: Safety, Pharmacokinetics and Pharmacodynamics Study of Inhaled QBW276 in Patients With Cystic Fibrosis (clinicaltrials.gov) - May 15, 2017
P1/2, N=56, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Initiation date: Jan 2016 --> Jul 2017 | Trial primary completion date: Nov 2017 --> Jul 2019
- QBW276 / Novartis
Enrollment change, Trial withdrawal: Safety, Pharmacokinetics and Pharmacodynamics Study of Inhaled QBW276 in Patients With Cystic Fibrosis (clinicaltrials.gov) - Mar 14, 2016
P1/2, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Initiation date: Jan 2016 --> Jul 2017 | Trial primary completion date: Nov 2017 --> Jul 2019 N=46 --> 0 | Suspended --> Withdrawn
- QBW276 / Novartis
Trial suspension: Safety, Pharmacokinetics and Pharmacodynamics Study of Inhaled QBW276 in Patients With Cystic Fibrosis (clinicaltrials.gov) - Dec 11, 2015
P1/2, N=46, Suspended, Sponsor: Novartis Pharmaceuticals
N=46 --> 0 | Suspended --> Withdrawn Not yet recruiting --> Suspended
- | QBW276 / Novartis
New P1/2 trial: Safety, Pharmacokinetics and Pharmacodynamics Study of Inhaled QBW276 in Patients With Cystic Fibrosis (clinicaltrials.gov) - Oct 1, 2015
P1/2, N=46, Not yet recruiting, Sponsor: Novartis Pharmaceuticals